New results from Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) showed once-daily, oral baricitinib 4 mg helped ...

"Lilly and Incyte to seek approval of alopecia JAK inhibitor in children" was originally created and published by ...

Notably, in a post-hoc analysis which included adolescents who were diagnosed with severe AA less than 2 years before starting treatment, successful hair regrowth at 1 year was achieved in 80% and ...

Eli Lilly announced on Friday safety and efficacy results from two separate late-stage studies testing its approved drugs for ...

USA: A systematic review and network meta-analysis using Bayesian methods has found that deuruxolitinib 8 mg twice daily ...

Nektar Therapeutics is expected to announce topline data from the REZOLVE-AA trial in December 2025. The Food and Drug Administration (FDA) has granted Fast Track designation to rezpegaldesleukin for ...

New results from Eli Lilly (LLY) and Incyte (INCY) showed once-daily, oral baricitinib 4 mg helped the majority of adolescent patients with severe ...

The AI tool offers precise alopecia assessment, improving accuracy and sensitivity over traditional methods like the SALT ...

SAN FRANCISCO, July 29, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for ...

Dermatologists, who recently celebrated the US Food and Drug Administration's (FDA's) approval of the world's first oral systemic treatment for adults with severe alopecia areata (AA), are now looking ...

This trial is the first and largest study specifically designed to evaluate children and adolescents with severe alopecia areata, a population often underrepresented ...